Merotocin
Merotocin (INN) (developmental code name FE-202767), also known as carba-1-(4-FBzlGly7)dOT, is a peptidic agonist of the oxytocin receptor that was derived from oxytocin. It is under development by Ferring Pharmaceuticals for the treatment of preterm mothers with lactation failure requiring lactation support, and is in phase II clinical trials for this indication. Merotocin is potent ( EC50 1000-fold over the related vasopressin receptors). See also * Carbetocin * Demoxytocin * TC OT 39 TC OT 39 is a non- peptide partial agonist of the oxytocin and vasopressin V2 receptors (Ki = 147 nM and >1000 nM, respectively) and antagonist of the vasopressin V1A receptor (Ki = 330 nM). See also * WAY-267,464 WAY-267464 is a potent, s ... * WAY-267,464 References External links Pipeline - Ferring PharmaceuticalsMerotocin - AdisInsight Oxytocin receptor agonists Cyclic peptides {{drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]